Strata Critical Medical Lifts 2026 Outlook After 61% Revenue Jump in Q2
SRTA sits 56% above its 52-week low of $3.675.
Summary
Strata Critical Medical posted Q2 2026 revenue of $72.5M, up 60.7% YoY, and raised its full-year revenue and Adjusted EBITDA guidance. The quarter also saw three acquisitions close and a deal signed to take over Statline's organ placement relationships.
Key Events · Earnings and Guidance · SRTA
-
Q2 Revenue Surges 61%
Total revenue reached $72.5 million, driven by 6.9% growth in Logistics and the addition of the Clinical segment, which contributed $24.3 million.
-
Full-Year Guidance Raised
2026 revenue guidance increased to $285-295 million (from $260-275 million) and Adjusted EBITDA to $33-35 million (from $29-33 million), reflecting strong performance and acquisition contributions.
-
Adjusted EBITDA Hits $7.9M
Adjusted EBITDA of $7.9 million (10.9% margin) was up from $2.5 million a year ago, driven by higher gross profit and operating leverage.
-
Three Bolt-On Acquisitions Closed
Completed acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program, and Ohio Valley Perfusion Associates, adding over $6 million in projected annualized Adjusted EBITDA.
Analysis · SRTA · Industrial Applications And Services
A 61% year-over-year revenue surge to $72.5 million—fueled by organic logistics growth and the new clinical business—powered Strata Critical Medical's strong second quarter. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance, underscoring confidence in its acquisition-led expansion. Adjusted EBITDA of $7.9 million and positive free cash flow of $2.9 million highlight improving profitability, even as a GAAP net loss of $10.5 million reflects non-cash charges from earn-out revaluations and accelerated amortization. While the updated outlook and operational momentum point to continued growth, integration risks from the three bolt-on acquisitions completed during the quarter warrant attention.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRTA was trading at $5.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $480.2M. The 52-week trading range was $3.68 to $6.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.